Odyssey Therapeutics, Inc., a biotechnology company pioneering next generation precision immunomodulators for autoimmune and inflammatory diseases, today announced the appointment of William Roush, Ph.D., as executive vice president and head of small molecule research. In this role, Dr. Roush will be responsible for overseeing the prosecution of Odyssey’s small molecule, preclinical portfolio from target selection into early development.

“As a renowned scientist, Dr. Roush developed innovative solutions to complex problems in organic and medicinal chemistry, and under his leadership, has led multiple drug discovery programs from ideation into clinical development,” said Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics. “With the addition of Dr. Roush to our team of drug hunters, I am confident Odyssey will continue to develop the best therapeutic candidates to potentially change the standard of care for patients living with serious immune diseases.”

Dr. Roush completed his Ph.D. degree in chemistry at Harvard University under the direction of Nobel Laureate R. B. Woodward. He held academic positions at MIT, Indiana University, the University of Michigan and most recently, the Scripps Research Institute where he is Emeritus Professor of Chemistry. Dr. Roush is the author of 380 peer-reviewed publications spanning organic and medicinal chemistry. Prior to joining Odyssey, he was the executive vice president of chemistry at IFM Therapeutics and oversaw the discovery of several product candidates for cancer and inflammation that are now in clinical development.

“The need for transformative medicines to improve patient outcomes is critical,” said Dr. Roush. “By collaborating with others at Odyssey, I hope to accelerate the discovery and development of small molecule medicines to enhance the quality of life for patients.”

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering, developing and commercializing the next generation of autoimmune and inflammatory medicines. Since its founding in 2021, Odyssey has rapidly advanced its autoimmune and inflammatory programs from discovery into clinical development. With a comprehensive suite of tools for discovery and development, and a team of expert drug hunters, Odyssey can tackle drug targets with the highest clinical potential in a modality-agnostic manner. For more information, please visit odysseytx.com and follow Odyssey Therapeutics on X (formerly Twitter) and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240801136474/en/